Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 264 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the... December 17, 2021 Doctors Think Woman Has A Brain Tumor, But Then They Open... June 17, 2019 Immunotherapy treatment fast tracked to treat lung cancer patients in England January 28, 2022 Nanoparticle Trains Immune Cells to Attack Cancer December 4, 2020 Load more HOT NEWS ASCO20 Virtual Research Round Up Podcast: Leukemia, Colorectal Cancer, and Lung... New Research in Treating Metastatic Breast Cancer, Preventing Breast Cancer, and... How you can do your part in the AI transformation of... Study Finds the Cost of Treating Metastatic Breast Cancer Could More...
